Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.
Contact | 
Explore Technologies



H11 and 2F3 cell line


Stanford Reference:

13-001


Abstract


Researchers in Dr. Shoshana Levy’s lab have created a pro B cell lines that provides the first B cell lineage tumors in a C57BL mouse strain. The cell lines, known as H11 and 2F3, were made by transducing mouse bone marrow with BCR-ABL retrovirus. The H11 and 2F3 cell lines may be used in immunotherapy and tumor biology research.

Stage of research
The H11 cell line has been used to develop a whole tumor cell vaccine in adoptive cell therapy studies.


Applications


  • Tumor biology
  • Immunology

Advantages


  • First B cell lineage tumors in C57BL strain of mouse
  • Grows in tissue culture
  • Transplantable in syngeneic mice
  • Cell line is MHC class II negative
  • Cells can be loaded with reagents and labeled for visualization
  • Can isolate ample numbers of these cells to prepare vaccine

Publications



Related Web Links



Innovators & Portfolio



Date Released

 12/19/2014 12:00
 

Licensing Contact


Michael Bellas, Licensing Associate
Request Info

79-066 Mouse Anti-Human Hybridomas: 12E7, L243, L17F12, L368
82-068 Hybridomas 3B12, an Anti-Human Leucocyte Reagent, and Hybridoma 4H9, an Anti-Human T Cell Reagent
83-007 Anti-Leu-12 (CD19) Monoclonal Antibody, 4G7

more technologies »

Related Keywords


B-cell immunology   cancer vaccine   cancer: lymphoma   LS: research tool: cell line   LS: research tool: reagent   research: cancer   tumor immunology